IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded 50mg ultram and brand equivalent (generic) pharmaceuticals and veterinary products in the U. Forward-looking statements are merely the Company’s current predictions of future events. (OTCBB:ABLA) (BSE:ABRX) today announced that the U. Johnson Pharmaceutical Research Institute’s Ultram(R) Tablets which is indicated for the management of moderate to moderately severe pain. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should 50mg ultram our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. Tramadol is used to treat persistent moderate to severe pain and is the generic equivalent of 50mg ultram ultram(r) tablets marketed by Johnson & Johnson. For example, statements about the Company’s operations, capital-raising transactions and financial accounting, the current or expected market size for its products, the success of current or future product offerings, the research and development efforts and the Company’s ability to file for and obtain U. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50mg. Securities and Exchange Commission. Although we believe that these 50mg ultram statements are based upon reasonable assumptions, we cannot guarantee future results. And branded products through Bertek Pharmaceuticals 50mg ultram inc. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. These factors and additional information are discussed in the Company’s filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management. (Nasdaq: ELAB) announced today that it received final approval for Tramadol HCl, 50mg tablets, the generic alternative for the pain 50mg ultram treatment Ultram(R)(1). Earlier in the year, Able Labs announced that it entered into an ANDA Transfer and Marketing Agreement with IVAX Pharmaceuticals, Inc.